NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

计划入组 83 人 · 首次发布于 2009 年 3 月 5 日

A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer

计划入组 51 人 · 首次发布于 2009 年 12 月 15 日

Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer

计划入组 15 人 · 首次发布于 2024 年 3 月 29 日

Colorectal cancer vaccine (Oryx)

Sotorasib(Lumakras, Lumykras)

C₃₀H₃₀F₂N₆O₃

Colorectal Cancer(Envisagenics)

Austrian Breast & Colorectal Cancer Study Group

Austria

BORDEAUX COLORECTAL INSTITUTE ACADEMY

France

Cardiff Oncology

United States

Pelareorep Shows 33% Response Rate in KRAS-Mutant Colorectal Cancer, Tripling Standard-of-Care Outcomes

BridgeBio Oncology Secures $450M SPAC Deal to Advance KRAS Inhibitor Pipeline

Quadruple Immunotherapy Shows Durable Complete Response in MSS Metastatic Colorectal Cancer but Lacks Reproducibility